Horizon Therapeutics stock plunges on report FTC is preparing to block Amgen deal

The deal is a bid to strengthen Amgen's drug portfolio as it prepares to face several patent expirations for key treatments over the next decade.

from Health and Science https://ift.tt/h1v6YwD
https://ift.tt/Ykit1fh
https://ift.tt/vEdHXCU